Karyopharm Therapeutics Inc. (KPTI)

Market Cap	38.79M
Revenue (ttm)	142.13M
Net Income (ttm)	-62.52M
Shares Out	8.64M
EPS (ttm)	-12.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,687
Open	4.530
Previous Close	4.480
Day's Range	4.350 - 4.600
52-Week Range	3.510 - 17.400
Beta	0.33
Analysts	Buy
Price Target	48.50 (+980.18%)
Earnings Date	May 12, 2025

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2024, Karyopharm Therapeutics's revenue was $145.24 million, a decrease of -0.55% compared to the previous year's $146.03 million. Losses were -$76.42 million, -46.60% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $48.5, which is an increase of 980.18% from the latest price.

Price Target

$48.5

(980.18% upside)

Analyst Consensus: Buy